Sera Announces Publication Acceptance for PRIME Study
Sera Prognostics (NASDAQ: SERA) announced that the PRIME study — Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs — was accepted for publication in a peer-reviewed medical journal on Nov. 24, 2025. The study is described as one of the largest preterm birth studies and its abstract was previously selected as a late-breaking abstract for podium presentation at the Society for Maternal-Fetal Medicine annual meeting earlier in 2025. Management said they will share the PRIME manuscript data upon publication and present findings at upcoming medical meetings and events with research analysts.
Sera Prognostics (NASDAQ: SERA) ha annunciato che lo studio PRIME — Valutazione del rischio di prematurità combinata con interventi clinici per migliorare gli esiti neonatali — è stato accettato per pubblicazione in una rivista medica peer-reviewed il 24 novembre 2025. Lo studio è descritto come uno dei più grandi studi sulla nascita preterm e il suo abstract è stato precedentemente selezionato come un late-breaking abstract per una presentazione al podio durante la riunione annuale della Society for Maternal-Fetal Medicine agli inizi del 2025. La direzione ha dichiarato che condividerà i dati del manoscritto PRIME al momento della pubblicazione e presenterà i risultati nelle prossime conferenze mediche ed eventi insieme agli analisti di ricerca.
Sera Prognostics (NASDAQ: SERA) anunció que el estudio PRIME — Evaluación del riesgo de prematuridad combinada con intervenciones clínicas para mejorar los resultados neonatales — fue aceptado para publicación en una revista médica revisada por pares el 24 de noviembre de 2025. El estudio se describe como uno de los mayores estudios sobre el nacimiento pretérmino y su resumen ya fue seleccionado previamente como un late-breaking abstract para presentación en el podio en la reunión anual de la Society for Maternal-Fetal Medicine a principios de 2025. La gerencia indicó que compartirán los datos del manuscrito PRIME tras la publicación y presentarão los hallazgos en próximas reuniones médicas y eventos con analistas de investigación.
Sera Prognostics (NASDAQ: SERA)는 PRIME 연구 — 미숙아 위험 평가를 임상 개입과 결합하여 신생아 예후를 개선하는 것 — 가 동료 검토를 거친 의학 저널에 2025년 11월 24일에 게재 승인되었다고 발표했습니다. 이 연구는 조산 연구 중 가장 큰 연구 중 하나로 설명되며, 그 초록은 2025년 초 산모-태아 의학 학회 연례회의에서 기조 발표를 위한 late-breaking abstract로 이미 선정되었습니다. 경영진은 게시 후 PRIME 원고 데이터를 공유하고 연구 분석가들과 함께 다가오는 의학 학회 및 행사에서 결과를 발표할 것이라고 말했습니다.
Sera Prognostics (NASDAQ: SERA) a annoncé que l’étude PRIME — Évaluation du risque de prématurité associée à des interventions cliniques pour améliorer les résultats néonataux — a été acceptée pour publication dans une revue médicale évaluée par des pairs le 24 novembre 2025. L’étude est décrite comme l’une des plus grandes études sur l’accouchement prématuré et son résumé a été préalablement sélectionné comme un late-breaking abstract pour une présentation sur scène lors de la réunion annuelle de la Society for Maternal-Fetal Medicine au début de 2025. La direction a déclaré qu’elle partagera les données du manuscrit PRIME une fois la publication effectuée et présentera les résultats lors des prochaines réunions médicales et événements avec des analystes de recherche.
Sera Prognostics (NASDAQ: SERA) gab bekannt, dass die PRIME-Studie — Risikobewertung von Frühgeburten kombiniert mit klinischen Interventionen zur Verbesserung der neonatalen Ergebnisse — am 24. November 2025 zur Veröffentlichung in einer begutachteten medizinischen Fachzeitschrift akzeptiert wurde. Die Studie wird als eine der größten Frühgeburt-Studien beschrieben und ihr Abstract wurde zuvor als late-breaking abstract für eine Vortragspräsentation auf der Jahrestagung der Society for Maternal-Fetal Medicine Anfang 2025 ausgewählt. Das Management sagte, sie würden die PRIME-Manuskript-Daten nach der Veröffentlichung teilen und die Ergebnisse auf kommenden medizinischen Meetings und Veranstaltungen mit Forschungsanalysten präsentieren.
Sera Prognostics (NASDAQ: SERA) أعلنت أن دراسة PRIME — تقييم مخاطر الولادة المبكرة المجمّع مع التدخلات السريرية لتحسين النتائج الحديثة لدى حديثي الولادة — قد نُقلت للنشر في مجلة طبية مُقيِّمة من قبل peer-review في 24 نوفمبر 2025. وتوصف الدراسة بأنها واحدة من أضخم الدراسات حول الولادة المبكرة، وقد تم اختيار ملخصها سابقاً كـ late-breaking abstract لعرضها على المنصة في الاجتماع السنوي لجمعية طب الأم والجنين في أوائل 2025. وأفادت الإدارة بأنها ستشارك بيانات مخطوطة PRIME عند النشر وستعرض النتائج في المؤتمرات الطبية القادمة والفعاليات مع محللي البحث.
- PRIME study accepted for peer-reviewed publication
- Abstract chosen as late-breaking podium presentation at SMFM 2025
- Company committed to sharing manuscript data at upcoming medical meetings
- None.
The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year
The PRIME study's abstract data was selected as a late-breaking abstract for podium presentation earlier this year at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting.
"We look forward to sharing PRIME manuscript data upon publication at upcoming medical meetings and through events with our research analysts," said Zhenya Lindgardt, President and CEO of Sera Prognostics.
About Sera Prognostics, Inc.
Sera Prognostics is a health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. The company's PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test for early, individualized risk prediction of spontaneous preterm birth. Sera Prognostics is headquartered in Salt Lake City, Utah.
About The PreTRM® Test
The PreTRM Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to sharing PRIME manuscript data upon publication at upcoming medical meetings and through events with our research analysts; and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Contacts:
Investor Contact
Jennifer Zibuda, Head of Investor Relations
jzibuda@sera.com
+1 (801) 396-8043
Media Contact
Bridget Mahoney at Allison Worldwide
sera@allisonworldwide.com
+1 (716) 868-7505
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-announces-publication-acceptance-for-prime-study-302624071.html
SOURCE Sera Prognostics, Inc.
FAQ
What did Sera Prognostics (SERA) announce on November 24, 2025 about the PRIME study?
How significant is the PRIME study acceptance for SERA investors?
When will Sera share the PRIME manuscript data for SERA investors?
What is the PRIME study about and why does it matter for SERA (NASDAQ: SERA)?
Was the PRIME study presented publicly before publication for SERA?
